Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic

Background. Tocilizumab is an anti-IL-6 therapy widely adopted in the management of the so-called “cytokine storm” related to SARS-CoV-2 virus infection, but its effectiveness, use in relation to concomitant corticosteroid therapy and safety were unproven despite widespread use in numerous studies,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahroum, Naim, Watad, Abdulla, Bridgewood, Charlie, Mansour, Muhammad, Nasr, Ahmad, Hussein, Amr, Khamisy-Farah, Rola, Farah, Raymond, Gendelman, Omer, Lidar, Merav, Shoenfeld, Yehuda, Amital, Howard, Kong, Jude Dzevela, Wu, Jianhong, Bragazzi, Nicola Luigi, McGonagle, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431489/
https://www.ncbi.nlm.nih.gov/pubmed/34501738
http://dx.doi.org/10.3390/ijerph18179149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431489/
https://www.ncbi.nlm.nih.gov/pubmed/34501738
http://dx.doi.org/10.3390/ijerph18179149

Ejemplares similares